Latest Tanabe Pharma News & Updates
See the latest news and media coverage for Tanabe Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about Tanabe Pharma
In short: Tanabe Pharma underwent a major rebranding and structural reorganization following its acquisition by Bain Capital and the sale of its ALS business.
Company announcements
-
Tanabe Pharma announces EU marketing authorization for Onerji®
Onerji® treats motor fluctuations in advanced Parkinson's disease via continuous subcutaneous infusion. Phase 3 trials showed increased ON time and reduced OFF time.
-
Tanabe Pharma receives GHIT Fund grant for anti-malarial drugs
The JPY 700 million grant supports two-year preclinical development with MMV and UGA for next-generation drugs effective against falciparum and vivax malaria.
-
Tanabe Pharma completes edaravone business transfer to Shionogi
The transfer includes IP and sales rights for RADICAVA/Radicut in Japan, US, Canada, and others sequentially. It strengthens Tanabe's financial foundation for pipeline investments.
-
Tanabe Pharma dissolves BIKEN Co. joint venture
BIKEN Foundation acquires Tanabe Pharma's shares on April 1, 2026, making BIKEN its wholly owned subsidiary. They continue as manufacturer and distributor.
Media coverage
-
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi
Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of Tanabe Pharma Corporation, today announced the finalization of the transfer of the RADICAVA (edaravone) business...
-
Tanabe readying new dersimelagon data for FDA filing
Japan’s Tanabe Pharma Corporation has announced detailed results from the Phase III INSPIRE study of investigational oral dersimelagon in people living with erythropoietic protoporphyria (EPP...
-
Exclusive: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Tanabe Pharma's dersimelagon shows positive Phase 3 results for EPP/XLP patients, extending sunlight exposure time before symptom onset compared to placebo at AAD meeting.
-
Bain-Owned Tanabe Pharma Targets Global Deals To Fuel Growth
Bain Capital-owned Tanabe Pharma Corp. is on the hunt for licensing deals abroad to bring medicines into Japan, betting that unmet patient demand and easing...
Track Tanabe Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore